• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    ReAlta raises $40M to advance HIE drug pegtarazimod

    BUSINESSWIRE

    ReAlta Appoints Berman as CEO, Kia Motesharei as President & COO

    PHARMIWEB

    ReAlta: RLS-0071 Cuts Brain Inflammation in Preclinical Test

    BUSINESSWIRE

    ReAlta Life Sciences Reveals New RLS-0071 Data at PAS 2025

    BUSINESSWIRE

    ReAlta to Present Data from Hypoxic Ischemic Encephalopathy Program

    BUSINESSWIRE

    ReAlta Life Sciences Appoints Laurie Glimcher, M.D., as Director

    BUSINESSWIRE

    ReAlta Appoints Biotech Leader Andrew Miller To Board

    BUSINESSWIRE

    ReAlta Appoints Dr. Lewis T. “Rusty” Williams as Board Chairman

    BUSINESSWIRE

    ReAlta Doses First Patient In Phase 2 RLS-0071 GVHD Study

    BUSINESSWIRE

    ReAlta Life Sciences Appoints Peter Ho, Ph.D., as Head of Business Development

    BUSINESSWIRE

    Biopharmaceutical Company ReAlta Hires New CEO, R&D Head

    CONTRACT PHARMA

    ReAlta Life Sciences Appoints New CEO And Chief R&D Officer

    BUSINESSWIRE

    ReAlta Life Sciences Strengthens Board of Directors

    BUSINESSWIRE

    ReAlta Life Sciences Strengthens Board of Directors

    BUSINESSWIRE

    ReAlta Announces Poster Presentation at the European Respiratory Society

    BUSINESSWIRE

    ReAlta Life Sciences Announces Poster Presentation at Annual Meeting

    BUSINESSWIRE

    FDA Grants FTD to ReAlta’s RLS-0071 for Hypoxic-Ischemic Encephalopathy

    BUSINESSWIRE

    ReAlta doses first subjects in Phase Ib severe asthma therapy trial

    CLINICALTRIALSARENA

    ReAlta Life Sciences Announces Poster Presentation at the AAN 2022

    BUSINESSWIRE

    ReAlta Life Sciences Receives $3.2 Million Grant from Virginia Catalyst

    BIOSPACE

    Statewide Collaboration Leads the Way in Closing Gaps in Vaccine Administration

    BUSINESSWIRE

    ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071

    BUSINESSWIRE

    ReAlta Life Sciences Doses First Subject in Ph 1 Volunteers of RLS-0071

    BUSINESSWIRE

    ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071

    BUSINESSWIRE

    ReAlta Life Announces USFDA Clearance of First Investigational NDA for RLS-0071

    BUSINESSWIRE

    ReAlta Life Sciences Closes $14 Million Series A2 Financing

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.